CDKN2A and acute lymphoblastic leukemia: Considering that Cdkn2a expression is lost in about 25% of t(12;21)+ pre-B ALL patients, both studies suggest that the inactivation of Cdkn2a is an event that contributes to accelerate leukaemia development [139].